Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy
 and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as neoadjuvant
 chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2 and the CTX 600mg/m2,21day/cycle).At the
 same time give daily oral exemestane 25mg for 12 weeks.Then assess the efficacy and safety of
 TAC and Exemestane.
The investigators select the postmenopausal patients with breast cancer who is confirmed by
 core needle biopsy and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as
 neoadjuvant chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2 and the CTX
 600mg/m2,21day/cycle).At the same time give daily oral exemestane 25mg for 12 weeks.Then
 assess the efficacy and safety of TAC and Exemestane.
Inclusion Criteria:

 1. Karnofsky ≥ 70

 2. Provision of informed consent

 3. Pathological confirmation of invasive ductal carcinoma and estrogen receptor is
 positive

 4. Tumor stage(TNM):T2-4bN0-3M0

 5. Premenopausal woman

 6. Not previously received treatment with bisphosphonate

 7. Laboratory criteria:

 -  PLT ≥ 100*109/L

 -  WBC ≥ 4000/mm3

 -  HGB ≥ 10g/dl

 -  GOT,GPT,ALP ≤ 2*ULN

 -  TBIL,DBIL,CCr ≤ 1.5*ULN

 Exclusion Criteria:

 1. Pregnant or lactation woman

 2. History of organ transplantation

 3. With mental disease

 4. With severe infection or active gastrointestinal ulcers

 5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or
 diabetes

 6. Disease-free period of other malignant tumor is less than 5 years(except cured basal
 cell skin cancer and cervical carcinoma in situ)

 7. With heart disease

 8. Experimental drug allergy